Description

Tas-102 is a novel oral nucleoside antitumor agent, a combination of trifluridine and tipiracil hydrochloride. This compound is specifically designed to inhibit tumor cell proliferation through a dual mechanism of action, offering a targeted therapeutic approach. It is primarily utilized in advanced pharmaceutical research and development, particularly for the treatment of refractory metastatic colorectal cancer and other solid tumors. Global pharmaceutical manufacturers and advanced research institutions rely on this high-purity active pharmaceutical ingredient for developing innovative oncology treatments.

Application

• Oncology Drug Development: Primary active pharmaceutical ingredient (API) in the formulation of oral chemotherapeutic agents for colorectal cancer.
• Clinical Research: Serves as a critical reference standard and raw material in preclinical and clinical trials for evaluating efficacy and safety.
• Pharmaceutical Synthesis: Used as a key intermediate in the synthesis of more complex anticancer drug candidates and prodrugs.
• Mechanistic Studies: Employed in biochemical and pharmacological research to study thymidine phosphorylase inhibition and DNA incorporation mechanisms.
• Combinatorial Therapy Research: Investigated in combination with other anticancer agents to enhance therapeutic outcomes and overcome drug resistance.
• Generic Drug Manufacturing: Sourced by manufacturers for the production of generic versions following patent expiry, ensuring supply for global healthcare systems.

Basic Information

Product Name	Tas-102
CAS No.	733030-01-8
Molecular Formula	C₉H₁₁F₃N₂O₅ • C₉H₁₃ClN₄O₄
Molecular Weight	534.85 g/mol (for the combination)
Synonyms	Trifluridine/Tipiracil Hydrochloride; TAS-102; FTD/TPI; Lonsurf (Brand Name); Trifluridine and Tipiracil Hydrochloride Combination; TAS 102; 5-Trifluoromethyl-2'-deoxyuridine / 5-Chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione Hydrochloride; FTY/TPI
EINECS	Contact for details

Quality Control

Our Tas-102 is manufactured under strict cGMP guidelines to ensure the highest standards of purity and consistency required for pharmaceutical applications. Each batch undergoes comprehensive analytical testing, including HPLC for assay and impurity profiling, identification by spectroscopic methods (IR, NMR), and stringent tests for residual solvents and heavy metals. A comprehensive Certificate of Analysis (COA) is provided with each shipment, detailing all specifications and confirming compliance with relevant pharmacopeial standards.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccants or inert atmosphere packaging to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Related Substances (HPLC)	Individual impurity: ≤ 0.5%; Total impurities: ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm
Microbial Limits	Complies with Ph. Eur. 2.6.12/2.6.13

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.